2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
7
Carcinoma, Non-Small-Cell Lung
4
Squamous Cell Carcinoma of Head and Neck
3
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumors, Adult
1
Skin Neoplasms
1
Lung Neoplasms
1
Lung Diseases
1
Colorectal Neoplasms
1
Carcinoma
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Interventions
Fluorouracil
498
Bevacizumab
476
Oxaliplatin
450
Leucovorin
442
Irinotecan
408
Cetuximab
318
Capecitabine
317
pembrolizumab
142
Folfox protocol
128
Panitumumab
117
regorafenib
105
Colonoscopy
88
Nivolumab
82
IFL protocol
81
Drug Therapy
77
trifluridine tipiracil drug combination
73
Radiotherapy
66
HMPL-013
65
Blood Specimen Collection
52
Gemcitabine
49
Specimen Handling
47
Standard of Care
45
Neoadjuvant Therapy
45
Magnetic Resonance Spectroscopy
44
Biopsy
44
Chemotherapy, Adjuvant
41
Trifluridine
40
atezolizumab
39
Cyclophosphamide
39
Surveys and Questionnaires
38
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colorectal Neoplasms
×
Toll-Like Receptor 1
×
Clear all
NCT05576077
2025-03-10
STARLING
Turnstone Biologics, Corp.
Phase 1
Terminated
31 enrolled